Interstitial lung diseases
Oral presentation
Sarcoidosis: novel insights in disease epidemiology, immunology and treatment
Translational
Methods :
Cell and molecular biology, Imaging, Pulmonary function testing, General respiratory patient care, Epidemiology
09:30
Late Breaking Abstract - Deciphering disagreement: sarcoidosis management and the role of FDG-PET/CT
R. Donnelly(Dublin, Ireland)
COI
1
OA947
09:35
Effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis
V. Kahlmann(Rotterdam, Netherlands)
COI
2
OA948
09:40
BERYSARC: a multicentric control case study comparing chronic beryllium disease to pulmonary sarcoidosis
C. Rotenberg(Paris, France)
COI
3
OA949
09:45
Usual interstitial pneumonia (UIP) pattern in pulmonary sarcoidosis
G. Castelli(Padova, Italy)
COI
4
OA950
09:50
Late Breaking Abstract - Evaluation of the antifibrotic activity of bexotegrast, a dual αVβ6/αVβ1 integrin inhibitor, in precision-cut lung slices prepared from non-IPF interstitial lung disease explants
J. Schaub(South San Francisco, United States)
COI
5
OA951
09:55
Deciphering the genetic tapestry: Insights into sarcoidosis across diverse populations with the MESARGEN Consortium
N. Rivera(Stockholm, Sweden)
COI
6
OA952
10:00
Dissecting the immune cell niche in pulmonary sarcoidosis – CXCL10+ monocyte-derived macrophages are potential drivers of TH17.1 inflammation
J. Ruwisch(Hannover, Germany)
COI
7
OA953
10:05
Sarcoidosis in the United Kingdom: Findings from the first decade of the UK ILD Registry
A. Achaiah(Oxford, United Kingdom)
COI
8
OA954
10:10
RESOLVE-LUNG, a multinational, randomized, placebo-controlled Phase II trial of namilumab, an anti-GMCSF monoclonal antibody, in chronic pulmonary sarcoidosis: trial design and patient characteristics
B. van den Blink(Poortugaal, Netherlands)
COI
9
OA955
10:15
A population-based matched cohort study of sarcoidosis incidence, prevalence, and all-cause mortality. The HUNT study
A. Lunde(Harstad, Norway)
COI
10
OA956
10:20
Discussion and Q&A
11
OA957
. . .
